Skip to main content
SpringerLink
Log in

Oberflächenhyperthermie und regionale Tiefenhyperthermie

Sinnvolle Ergänzungen zur Chemo- und Strahlentherapie

  • zertifizierte fortbildung
  • Published:
Info Onkologie Aims and scope

Zusammenfassung

Die Hyperthermie hat in Form der Oberflächenhyperthermie und der regionalen Tiefenhyperthermie Einzug in internationale Leitlinien zur Therapie des Weichteilsarkoms und des Mammakarzinoms gehalten. Auch beim Zervixkarzinom gibt es erfolgversprechende Ergebnisse. Nach den Leitlinien der European Society of Hyperthermic Oncology (ESHO) wird sie stets im Rahmen einer Kombinationstherapie gemeinsam mit Chemo- und/oder Strahlentherapie angewandt, jedoch nie alleine. Die Hyperthermie ist insgesamt eine nebenwirkungsarme und sichere Therapieform, die jedoch nur in spezialisierten und nach den aktuellen Leitlinien handelnden Zentren mit der entsprechenden Erfahrung und Geräteausstattung angeboten werden sollte.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

1
2

Literatur

  1. ESMO/European Sarcoma Network Working Group. Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25 Suppl 3:iii102–12.

    Article  Google Scholar 

  2. Hand JW. Et al. Quality assurance guidelines for ESHO protocols. Int J Hyperthermia. 1989;5(4):421–8.

    Article  CAS  PubMed  Google Scholar 

  3. Wust P et al. Hyperthermia in combined treatment of cancer. Lancet Oncol. 2002;3(8):487–97.

    Article  CAS  PubMed  Google Scholar 

  4. Arcangeli G et al. Tumour response to heat and radiation: prognostic variables in the treatment of neck node metastases from head and neck cancer. Int J Hyperthermia. 1985;1(3):207–17.

    Article  CAS  PubMed  Google Scholar 

  5. Leopold KA et al. Cumulative minutes with T90 greater than Tempindex is predictive of response of superficial malignancies to hyperthermia and radiation. Int J Radiat Oncol Biol Phys. 1993;25(5):841–7.

    Article  CAS  PubMed  Google Scholar 

  6. Issels RD et al. Ifosfamide plus etoposide combined with regional hyperthermia in patients with locally advanced sarcomas: a phase II study. J Clin Oncol. 1990;8(11):1818–29.

    CAS  PubMed  Google Scholar 

  7. Wust P et al. Rationale for using invasive thermometry for regional hyperthermia of pelvic tumors. Int J Radiat Oncol Biol Phys. 1998;41(5):1129–37.

    Article  CAS  PubMed  Google Scholar 

  8. Strobl FF et al. CT fluoroscopy-guided closed-tip catheter placement before regional hyperthermia treatment of soft tissue sarcomas: 5-Year experience in 35 consecutive patients. Int J Hyperthermia. 2015 Dec 10:1-8. [Epub ahead of print]

  9. Bettaieb A et al. Hyperthermia: Cancer Treatment and Beyond. In: Rangel L (Edt.) Cancer Treatment - Conventional and Innovative Approaches. Rijeka: InTech Open Acsess. 2013. DOI: 10.5772/55795.

    Google Scholar 

  10. Raaphorst GP, Feeley MM. Comparison of recovery from potentially lethal damage after exposure to hyperthermia and radiation. Radiat Res. 1990;121(1):107–10.

    Article  CAS  PubMed  Google Scholar 

  11. Overgaard J et al. Randomised trial of hyperthermia as adjuvant to radiotherapy for recurrent or metastatic malignant melanoma. European Society for Hyperthermic Oncology. Lancet. 1995;345(8949):540–3.

    Article  CAS  PubMed  Google Scholar 

  12. van der Zee J et al. Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: a prospective, randomised, multicentre trial. Dutch Deep Hyperthermia Group. Lancet. 2000;355(9210): 1119–25.

    Article  PubMed  Google Scholar 

  13. Vernon CC et al. Radiotherapy with or without hyperthermia in the treatment of superficial localized breast cancer: results from five randomized controlled trials. International Collaborative Hyperthermia Group. Int J Radiat Oncol Biol Phys. 1996;35(4):731–44.

    Article  CAS  PubMed  Google Scholar 

  14. Jones EL et al. Randomized trial of hyperthermia and radiation for superficial tumors. J Clin Oncol. 2005;23(13):3079–85.

    Article  PubMed  Google Scholar 

  15. Issels RD (2008) Hyperthermia adds to chemotherapy. Eur J Cancer. 2008;44(17):2546–54.

    Article  CAS  PubMed  Google Scholar 

  16. Dahl O. Interaction of hyperthermia and chemotherapy. Recent Results Cancer Res. 1988;107:157–69.

    Article  CAS  PubMed  Google Scholar 

  17. Lepock JR. How do cells respond to their thermal environment? Int J Hyperthermia. 2005;21(8):681–7.

    Article  CAS  PubMed  Google Scholar 

  18. Zaarur N et al. Targeting heat shock response to sensitize cancer cells to proteasome and Hsp90 inhibitors. Cancer Res. 2006;66(3):1783–91.

    Article  CAS  PubMed  Google Scholar 

  19. Noessner E et al. Tumor-derived heat shock protein 70 peptide complexes are cross-presented by human dendritic cells. J Immunol. 2002;169(10):5424–32.

    Article  CAS  PubMed  Google Scholar 

  20. Milani V et al. Heat shock protein 70: role in antigen presentation and immune stimulation. Int J Hyperthermia. 2002;18(6):563–75.

    Article  CAS  PubMed  Google Scholar 

  21. Krawczyk PM et al. Mild hyperthermia inhibits homologous recombination, induces BRCA2 degradation, and sensitizes cancer cells to poly (ADP-ribose) polymerase-1 inhibition. Proc Natl Acad Sci U S A. 2011;108(24):9851–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Iliakis G et al. DNA double strand break repair inhibition as a cause of heat radiosensitization: re-evaluation considering backup pathways of NHEJ. Int J Hyperthermia. 2008;24(1):17–29.

    Article  CAS  PubMed  Google Scholar 

  23. Issels RD et al. for the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group (EORTC-STBSG); European Society for Hyperthermic Oncology (ESHO). Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study. Lancet Oncol. 2010;11(6):561–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Issels RD et al. Improved overall survival by adding regional hyperthermia to neo-adjuvant chemotherapy in patients with localized high-risk soft tissue sarcoma (HR-STS): Long-term outcomes of the EORTC 62961/ESHO randomized phase III study. Eur J Cancer. 2015;51(Supplement S3):Abstr 13LBA.

  25. Aubele P et al. Comparison of two chemotherapy regimens (AI vs. EIA) combined with regional hyperthermia (RHT) in high-risk soft-tissue sarcoma (HR-STS). Ann Oncol. 2012;23 (suppl 9):Abstr 1505P.

  26. von Mehren M et al. for the National Comprehensive Cancer Network. Soft tissue sarcoma, version 2.2014. J Natl Compr Canc Netw. 2014;12(4):473–83.

    Google Scholar 

  27. Harnicek D et al. Trabectedin combined with Hyperthermia: Characterization of enhanced drug-efficacy in human tumor cells. Ann Oncol. 2014;25(suppl 4): Abstr 1438P.

  28. Welz S et al. Thermoradiotherapy of the chest wall in locally advanced or recurrent breast cancer with marginal resection. Int J Hyperthermia. 2005;21(2):159–67.

    Article  CAS  PubMed  Google Scholar 

  29. Theriault RL et al. for the National Comprehensive Cancer Network. Breast cancer, version 3.2013: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2013;11(7):753–60; quiz 761.

    CAS  PubMed  PubMed Central  Google Scholar 

  30. Franckena M et al. Long-term improvement in treatment outcome after radiotherapy and hyperthermia in locoregionally advanced cervix cancer: an update of the Dutch Deep Hyperthermia Trial. Int J Radiat Oncol Biol Phys. 2008;70(4):1176–82.

    Article  PubMed  Google Scholar 

  31. Wessalowski R et al. Regional deep hyperthermia for salvage treatment of children and adolescents with refractory or recurrent non-testicular malignant germ-cell tumours: an open-label, non-randomised, single-institution, phase 2 study. Lancet Oncol. 2013;14(9):843–52.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medizinische Klinik und Poliklinik III, Klinikum der Universität München, Campus Großhadern, Marchioninistr. 15, 81377, München, Deutschland

    Bernhard Ismann, Eric Kampmann, Dorit Di Gioia, Falk Roeder, Sultan Abdel-Rahman &  Lars Lindner (Koordinator SarKUM)

Authors
  1. Bernhard Ismann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eric Kampmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dorit Di Gioia
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Falk Roeder
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sultan Abdel-Rahman
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Lars Lindner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lars Lindner.

Additional information

Interessenkonflikt

Die Autoren erklären, dass sie sich bei der Erstellung des Beitrags von keinen wirtschaftlichen Interessen leiten ließen. Folgende potenzielle Interessenkonflikte werden offen gelegt: B. Ismann: keine; E. Kampmann: keine; D. Di Gioia: keine; F. Roeder: keine; S. Abdel-Rahman und L. H. Lindner: Reisekostenunterstützung durch Dr. Sennevald Medizintechnik.

Der Verlag erklärt, dass die inhaltliche Qualität des Beitrags von zwei unabhängigen Gutachtern geprüft wurde. Werbung in dieser Zeitschriftenausgabe hat keinen Bezug zur CME-Fortbildung. Der Verlag garantiert, dass die CME-Fortbildung sowie die CME-Fragen frei sind von werblichen Aussagen und keinerlei Produktempfehlungen enthalten. Dies gilt insbesondere für Präparate, die zur Therapie des dargestellten Krankheitsbildes geeignet sind.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ismann, B., Kampmann, E., Di Gioia, D. et al. Sinnvolle Ergänzungen zur Chemo- und Strahlentherapie. Info Onkol. 19, 34–42 (2016). https://doi.org/10.1007/s15004-016-5204-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15004-016-5204-4

Search

Navigation